Table 1 Baseline characteristics of patients in the erenumab clinical trials [31, 43]
From: Migraine day frequency in migraine prevention: longitudinal modelling approaches
Characteristic | Episodic migrainea (NCT02456740) | Chronic migraineb (NCT02066415) | ||
|---|---|---|---|---|
Group | Placebo | Erenumab 140 mg | Placebo | Erenumab 140 mg |
Number of patients | 319 | 319 | 286 | 190 |
Mean age (SD) | 41.3 (11.2) | 40.4 (11.1) | 42.1 (11.3) | 42.9 (11.1) |
Sex, n (%) | ||||
 Male | 45 (14.1) | 47 (14.7) | 60 (21.0) | 30 (15.8) |
 Female | 274 (85.9) | 272 (85.3) | 226 (79.0) | 160 (84.2) |
Race, n (%) | ||||
 White | 277 (86.8) | 293 (91.8) | 268 (93.7) | 184 (96.8) |
 Black | 24 (7.5) | 18 (5.6) | 11 (3.8) | 6 (3.2) |
 Other | 18 (5.6) | 8 (2.5) | 7 (2.4) | 0 (0.0) |
Baseline MMD | 8.2 (± 2.5) | 8.3 (± 2.5) | 18.2 (± 4.7) | 17.8 (± 4.7) |